



Small, but heading for the big time

Nanobiotix revenue for Q3 2015

Paris, France, November 13, 2015 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the third quarter of 2015.

Income statement at September 30, 2015

<i>In €</i>	Q3 2015 <i>09/30/2015</i> <i>(9 months)</i>	Q3 2014 <i>09/30/2014</i> <i>(9 months)</i>
Revenues	140,816	140,570
Of which :		
<i>License</i>	137,542	137,541
<i>Services</i>	3,274	3,029

Revenue for the third quarter of 2015

<i>In €</i>	Q3 2015	Q2 2015	Q1 2015	Q3 2014
Revenues	47,636	46,189	46,991	46,631
Of which :				
<i>License</i>	46,351	45,160	46,031	46,351
<i>Services</i>	1,285	1,029	960	280

Overview

Nanobiotix's revenue during Q3 2015 corresponds to the upfront payment (pro-rata share) received by the Company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead NanoXray product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. The upfront payment totaled €810,640, generating revenue of €46,351 over the period. The invoicing of services totaled €1,285 for Q3 2015. In total, revenue for the third quarter amounted to €47,636 which is fully in line with Company expectations.

In July 2015, Nanobiotix received authorization from the French National Agency for Medicines and Health Products (ANSM) to start a Phase I/II clinical trial in two new liver cancer indications (three patient populations), for its lead product, NBTXR3. The trial is a multinational, non-randomized, open Phase I/II study to evaluate the use of NBTXR3 with high precision radiation therapy, delivered as high dose fractions (SBRT - Stereotactic Body Radiation Therapy) in hepatocellular cancer (HCC) and liver metastasis.

This trial is part of the nanomedicine NICE consortium financed by Bpifrance. It represents a significant enlargement of the potential use of NBTXR3 targeting the fourth and fifth indications after Soft Tissue Sarcoma, Head and Neck cancer and Rectum cancer.

Forthcoming communications expected:

- Prostate cancer: regulatory approval for a phase I/II study in the US depending on FDA feedback, expected end of 2015
- Head & Neck cancer: Phase I/II study data expected in H1 2016
- Soft Tissue Sarcoma: Phase II/III pivotal study interim data expected at the end of H1 2016
- Liver cancers: multiple intermediate results of the Phase I/II study in the different indications expected in H2 2016
- Rectum cancer and other indications in Asia-Pacific: according to PharmaEngine calendar

Nanobiotix has already started to work on the most appropriate industrialization, commercialization and reimbursement routes in anticipation of a CE mark at the end of 2016.

The Company is also preparing for the future by expanding its pipeline with two other NanoXray products (NBTX-TOPO and NBTX-IV) and beyond.

The affiliate in US is expected to grow further in order to support Nanobiotix' clinical and corporate development.

•••

Next financial press release: revenue for Q4 2015 by February 26, 2016

•••

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck cancer, Liver cancers, Prostate cancer, Breast cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma, locally advanced Head and Neck cancer, Rectum cancer (PharmaEngine) and Liver cancers. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP). The company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com



Media relations

France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
nanobiotix@instinctif.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2014 annual financial report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.